{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:29:28Z","timestamp":1783913368388,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"vor","delay-in-days":341,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ijid.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T21:35:00Z","timestamp":1350941700000},"page":"e93-e100","source":"Crossref","is-referenced-by-count":96,"title":["High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Jesse T.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"DiazGranados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ijid.2012.08.005_bib0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","article-title":"Vancomycin: a 50-year reassessment","volume":"42","author":"Moellering","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(05)79166-2","article-title":"First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital","volume":"351","author":"Ploy","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2012.08.005_bib0015","unstructured":"US Centers for Disease Control and Prevention. CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). Atlanta, GA: CDC; 2011. Available at: http:\/\/www.cdc.gov\/HAI\/settings\/lab\/vrsa_lab_search_containment.html (accessed April 24, 2011)."},{"key":"10.1016\/j.ijid.2012.08.005_bib0020","series-title":"Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.ijid.2012.08.005_bib0025","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0030","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1086\/506568","article-title":"Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants","volume":"43","author":"Hageman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijantimicag.2008.04.011","article-title":"Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan","volume":"32","author":"Liao","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2012.08.005_bib0040","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/jac\/dkq200","article-title":"Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs","volume":"65","author":"Crompton","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2012.08.005_bib0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.clinthera.2006.08.003","article-title":"Case\u2013control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg\/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis","volume":"28","author":"Maclayton","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2012.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-0711-6-13","article-title":"Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections","volume":"6","author":"Neoh","year":"2007","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijid.2012.08.005_bib0060","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2012.08.005_bib0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijid.2012.08.005_bib0075","unstructured":"Review Manager. 5.1 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Col laboration; 2008."},{"key":"10.1016\/j.ijid.2012.08.005_bib0080","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00134-011-2130-7","article-title":"Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia","volume":"37","author":"Choi","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2012.08.005_bib0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10096-009-0837-y","article-title":"Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection","volume":"29","author":"Ferry","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0090","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1378\/chest.09-2453","article-title":"Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia","volume":"138","author":"Haque","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2012.08.005_bib0095","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijid.2012.08.005_bib0100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0105","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2012.08.005_bib0110","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.02135-08","article-title":"Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years","volume":"47","author":"Musta","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2012.08.005_bib0115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/597359","article-title":"Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin","volume":"48","author":"Price","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2334-10-159","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2mg\/l, by the broth microdilution method","volume":"10","author":"Wang","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0125","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.ijid.2010.09.013","article-title":"Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK","volume":"15","author":"Lewis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2010.02.026","article-title":"Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"67","author":"Neuner","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0135","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Risk factors for the failure of vancomycin in the treatment of MRSA bacteremia","author":"Lewis","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0140","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia","author":"Swami","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0145","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Vancomycin: the impact of MIC on clinical outcomes in MRSA bacteremia and pneumonia","author":"Wilhelm","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0150","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Outcomes in patients with MRSA bacteremia and reduced susceptibility to vancomycin","author":"Lustberg","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0155","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Epidemiology and outcomes of vancomycin treatment for MRSA bacteremia in an urban tertiary healthcare system: preliminary results","author":"Moore","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0160","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America Joint Meeting","article-title":"Predicting vancomycin susceptibility of infected MRSA strains based on clinical, epidemiological, and microbiologic variables","author":"Yamaki","year":"2008"},{"key":"10.1016\/j.ijid.2012.08.005_bib0165","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0170","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis","volume":"38","author":"Kalil","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2012.08.005_bib0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2012.08.005_bib0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","article-title":"Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations","volume":"204","author":"Holmes","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0195","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijid.2012.08.005_bib0200","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0205","series-title":"Solna","author":"Etest\u00ae package, insert","year":"2003"},{"key":"10.1016\/j.ijid.2012.08.005_bib0210","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0215","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.diagmicrobio.2010.08.006","article-title":"Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies","volume":"68","author":"Keel","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0220","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1128\/JCM.00221-09","article-title":"Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus","volume":"47","author":"Swenson","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2012.08.005_bib0225","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/606027","article-title":"Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance","volume":"200","author":"Bae","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/649572","article-title":"Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?","volume":"201","author":"Lalueza","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2012.08.005_bib0235","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.00918-10","article-title":"Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients","volume":"55","author":"Schweizer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2012.08.005_bib0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10156-010-0086-0","article-title":"Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mug\/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia","volume":"17","author":"Takesue","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2012.08.005_bib0245","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/JCM.02302-10","article-title":"Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates","volume":"49","author":"van Hal","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2012.08.005_bib50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1684-1182(10)60073-4","article-title":"Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates","volume":"43","author":"Huang","year":"2010","journal-title":"Journal Microbiol Immunol infect=Wei mian yu gan ran za zhi"},{"key":"10.1016\/j.ijid.2012.08.005_bib51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","article-title":"Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections","volume":"32","author":"Hsu","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2012.08.005_bib52","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.00939-06","article-title":"Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia","volume":"51","author":"Moise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2012.08.005_bib53","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J Antimicrobial Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971212012519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971212012519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T20:23:17Z","timestamp":1542658997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971212012519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1201971212012519"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2012.08.005","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}